Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PerFECT
- 26 Oct 2017 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.